Accumulating evidence indicates that CSF levels of p-tau change earlier than the tau PET signal in preclinical AD (208), reaching a relative plateau during the symptomatic stage of the disease (209,210), whereas the tau PET signal continues to increase in patients with AD dementia (211). Here, MAPT is linked to Alzheimer disease.